
    
      This is a Phase 1b, open-label, parallel-group, nonrandomized, multicenter study of PCI 32765
      420 mg once daily oral (PO) administration in combination with 2 different chemotherapy
      regimens in subjects with relapsed/refractory chronic lymphocytic leukemia (CLL)/small
      lymphocytic lymphoma (SLL).
    
  